Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* van den Broek Richard	2. Issuer Name and Ticker or Trading Symbol PHARMACYCLICS INC [ PCYC ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE	3. Date of Earliest Transaction (MM/DD/YYYY) 5/26/2015
(Street) SUNNYVALE, CA 94085 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	5/26/2015		U		29610	D	$261.25 ⁽¹⁾	0	I	by HSMR Advisors, LLC ⁽²⁾

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.90	5/26/2015		D			10000	⁽³⁾	12/17/2019	Common Stock	10000	⁽³⁾	0	D
Stock Option (Right to Buy)	$3.10	5/26/2015		D			7258	⁽³⁾	1/4/2020	Common Stock	7258	⁽³⁾	0	D
Stock Option (Right to Buy)	$6.63	5/26/2015		D			3619	⁽³⁾	4/1/2020	Common Stock	3619	⁽³⁾	0	D
Stock Option (Right to Buy)	$6.75	5/26/2015		D			3555	⁽³⁾	7/1/2020	Common Stock	3555	⁽³⁾	0	D
Stock Option (Right to Buy)	$8.12	5/26/2015		D			3139	⁽³⁾	10/1/2020	Common Stock	3139	⁽³⁾	0	D
Stock Option (Right to Buy)	$6.52	5/26/2015		D			4140	⁽³⁾	1/3/2021	Common Stock	4140	⁽³⁾	0	D
Stock Option (Right to Buy)	$5.76	5/26/2015		D			7500	⁽³⁾	12/9/2020	Common Stock	7500	⁽³⁾	0	D
Stock Option (Right to Buy)	$5.81	5/26/2015		D			20000	⁽³⁾	12/31/2020	Common Stock	20000	⁽³⁾	0	D
Stock Option (Right to Buy)	$6.01	5/26/2015		D			5240	⁽³⁾	4/1/2021	Common Stock	5240	⁽³⁾	0	D
Stock Option (Right to Buy)	$10.58	5/26/2015		D			2976	⁽³⁾	7/1/2021	Common Stock	2976	⁽³⁾	0	D
Stock Option (Right to Buy)	$11.31	5/26/2015		D			2784	⁽³⁾	10/3/2021	Common Stock	2784	⁽³⁾	0	D
Stock Option (Right to Buy)	$14.26	5/26/2015		D			7500	⁽³⁾	12/15/2021	Common Stock	7500	⁽³⁾	0	D
Stock Option (Right to Buy)	$15.02	5/26/2015		D			2409	⁽³⁾	1/3/2022	Common Stock	2409	⁽³⁾	0	D
Stock Option (Right to Buy)	$28.47	5/26/2015		D			1052	⁽³⁾	4/2/2022	Common Stock	1052	⁽³⁾	0	D
Stock Option (Right to Buy)	$59.28	5/26/2015		D			515	⁽³⁾	7/2/2022	Common Stock	515	⁽³⁾	0	D
Stock Option (Right to Buy)	$65.56	5/26/2015		D			510	⁽³⁾	10/1/2022	Common Stock	510	⁽³⁾	0	D
Stock Option (Right to Buy)	$49.00	5/26/2015		D			7500	⁽³⁾	11/9/2022	Common Stock	7500	⁽³⁾	0	D
Stock Option (Right to Buy)	$61.44	5/26/2015		D			546	⁽³⁾	1/2/2023	Common Stock	546	⁽³⁾	0	D
Stock Option (Right to Buy)	$79.67	5/26/2015		D			343	⁽³⁾	4/1/2023	Common Stock	343	⁽³⁾	0	D
Stock Option (Right to Buy)	$74.48	5/26/2015		D			3750	⁽³⁾	5/9/2023	Common Stock	3750	⁽³⁾	0	D
Stock Option (Right to Buy)	$85.39	5/26/2015		D			374	⁽³⁾	7/1/2023	Common Stock	374	⁽³⁾	0	D
Stock Option (Right to Buy)	$139.89	5/26/2015		D			226	⁽³⁾	10/1/2023	Common Stock	226	⁽³⁾	0	D
Stock Option (Right to Buy)	$108.44	5/26/2015		D			264	⁽³⁾	1/2/2024	Common Stock	264	⁽³⁾	0	D
Stock Option (Right to Buy)	$107.42	5/26/2015		D			280	⁽³⁾	4/1/2024	Common Stock	280	⁽³⁾	0	D
Stock Option (Right to Buy)	$95.08	5/26/2015		D			3750	⁽³⁾	5/9/2024	Common Stock	3750	⁽³⁾	0	D
Stock Option (Right to Buy)	$89.58	5/26/2015		D			456	⁽³⁾	7/1/2024	Common Stock	456	⁽³⁾	0	D
Stock Option (Right to Buy)	$115.80	5/26/2015		D			338	⁽³⁾	10/1/2024	Common Stock	338	⁽³⁾	0	D
Stock Option (Right to Buy)	$124.46	5/26/2015		D			318	⁽³⁾	1/2/2025	Common Stock	318	⁽³⁾	0	D
Stock Option (Right to Buy)	$257.015	5/26/2015		D			180	⁽³⁾	4/7/2025	Common Stock	180	⁽³⁾	0	D

Explanation of Responses:
( 1)	Price reflects aggregate per share consideration paid pursuant to the Tender Offer.
( 2)	Mr. van den Broek is the managing partner of HSMR Advisors, LLC.
( 3)	Pursuant to terms of the Agreement and Plan of Reorganization (the "Merger Agreement") dated March 4, 2015, by and between the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of AbbVie and Oxford Amherst LLC, a Delaware limited liability company and a direct wholly owned subsidiary of AbbVie this option was cancelled in exchange for a cash payment equal to the number of shares subject to the option multiplied by the difference between $261.25 and the exercise price of the option, subject to applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
van den Broek Richard C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE, CA 94085	X

Signatures
/s/ Richard van den Broek		5/27/2015
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.